A New View Of The Business of Biotech We’re fast approaching the 200th episode of the Business of Biotech podcast, and I’m incredibly grateful to our guests and listeners for your continued interest and engagement. A couple of weeks ago, we launched a new Business of Biotech landing page, where, in addition to hearing the charming voices of our guests, you can watch full-length videocasts (or, “vodcasts” for the hipsters among us) of each episode.
In addition to serving up all the latest episodes, we’ve categorized the entire library by the major theme discussed in each conversation (finance & capital markets, drug discovery, regulatory, etc.). Search up your favorite biotech leader and tune in. Grab a sack of popcorn and watch full screen. Or dock the video in the corner and go about your business. You can skip ahead, you can rewind – our crack development team pulled out all the bells and whistles. Check it out!
But first, check out this month’s selection of content for biotech builders from your friends at the Business of Biotech and Life Science Connect.
Matt Pillar, Business of Biotech host and chief editor, Bioprocess Online |
|
| | Biotech Beat | April 23, 2024 |
|
| ![]() | | by DR. CAROLINE LOEW | Seems like 10 years have passed since Carolyn Loew, Ph.D. joined us on the podcast. It was actually 2021 (episode 47, to be exact) and back then, she was with Glympse Bio. For the past year, she’s been CEO at immuno-oncology developer Mural Oncology. In this recent column for Life Science Leader, Dr. Loew reveals her opinion on what it’ll take for the decades-old immuno-oncology concept to crest the tipping point. Spoiler alert: science is just one part of the equation. | READ NOW → |
|
![]() | | by MICHAEL MEHLER | Michael Mehler is another Business of Biotech alum who joined us on episode 49 when he was with GSK. With experience there and at Immatics and Adaptimmune under his belt, Mehler has seen a few cell therapy supply chain snafus in his day. In this column authored for Cell & Gene, he offers a harrowing behind-the-scenes account of the patient and business impact of one such blunder. It didn’t end well. | READ NOW → |
|
| ![]() | | by LOUIS GARGUILO | We remain fascinated by the proposed Biosecurity Act fallout, recently marked by WuXi’s departure from the trade/lobbying group BIO (the Biotechnology Innovation Organization). No one’s been covering the unfolding story in more fair detail than our man on the scene, Outsourced Pharma Chief Editor Louis Garguillo. In this early April column, he peels another layer on the WuXi/BIO breakup, revealing some hypocrisy (or ignorance?) along the way. | READ NOW → |
|
![]() | | by DR. TAKEHIRO OKUMURA & ZEB KHAN | You can do some upstream manufacturing activity in non-GMP (Good Manufacturing Practice) environments, but in the FDA’s purview, will “GMP-like” be “GMP enough” for GMP? It depends, according to our friends Takehiro Okumura, Ph.D. and Zeb Khan at Takeda Pharmaceuticals. The Director of Cell Therapy Quality and head of quality manufacturing operations, respectively, sort out the risks and rewards in this exclusive for Bioprocess Online. | READ NOW → |
|
| | "We've been able to fund companies that have trouble finding money anywhere else. Our scientific diligence is so admired, that often we are like the stamp of approval that enables these companies to get future funding." | ― Karen Harris, CFO & Head Of Mission Related Investments, ADDF, Episode 195 |
|
| "I want to offer you $100. You will only receive $200. We compromise at $150. Neither of us are particularly happy, and neither of us are particularly unhappy. That's suboptimal." | ― Gavin Samuels, Ph.D., Chief Business Officer, CinRx Pharma, Episode 193 |
|
| "What I ultimately want to be judged by is the output. Are we creating better drugs than we could have otherwise? Do these drugs make a difference in patients' lives?" | ― Mike Nally, CEO, Generate:Biomedicines, Episode 194 |
|
| | | ![]() | Created exclusively for the leaders of new and emerging biopharma firms, the Business of Biotech podcast tackles organizational, funding, HR, regulatory, production and CMC considerations with insight from peer founders who have taken biologic therapies from an idea to clinical success. Check out our episode archive. | |
|
|
|
Ensure our newsletter reaches your inbox by following these whitelist instructions.
This newsletter is being sent to {{lead.Email Address}}. To cancel your subscription to the newsletter, please opt out. | © Copyright 2024 Vertmarkets, Inc. 5340 Fryling Rd Suite 100, Erie, PA 16510.
All rights reserved. All product names contained herein are the trademarks of their respective holders. |
|
|
|
|
